NELL2 Protein
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">NELL2 (Neural Epidermal Growth Factor-Like Protein 2)</th></tr>
<tr><td>Gene</td><td>[NELL2](/genes/NELL2)</td></tr>
<tr><td>UniProt ID</td><td>[Q9N465](https://www.uniprot.org/uniprot/Q9N465)</td></tr>
<tr><td>Molecular Weight</td><td>~100 kDa</td></tr>
<tr><td>Localization</td><td>Secreted, extracellular</td></tr>
<tr><td>Family</td><td>NELL family, thrombospondin type-1 domain-containing proteins</td></tr>
<tr><td>Brain Expression</td><td>High in cortex, hippocampus, substantia nigra</td></tr>
</table>
</div>
Overview
NELL2 (Neural Epidermal Growth Factor-like protein 2) is a secreted glycoprotein that plays critical roles in neural development, synaptic plasticity, and neuronal survival [1]. Originally discovered as a protein expressed preferentially in the nervous system, NELL2 has emerged as an important neurotrophic factor with potential therapeutic applications in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease [2].
NELL2 belongs to the NELL family of proteins, which includes NELL1 and NELL2 in humans. These proteins are characterized by multiple epidermal growth factor (EGF)-like domains and von Willebrand factor type C (vWC) domains, which mediate protein-protein interactions and calcium-dependent binding [3]. The unique structure of NELL2 enables it to function as both a signaling molecule and an extracellular scaffold protein.
Structure and Molecular Biology
Protein Domain Architecture
...NELL2 Protein
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">NELL2 (Neural Epidermal Growth Factor-Like Protein 2)</th></tr>
<tr><td>Gene</td><td>[NELL2](/genes/NELL2)</td></tr>
<tr><td>UniProt ID</td><td>[Q9N465](https://www.uniprot.org/uniprot/Q9N465)</td></tr>
<tr><td>Molecular Weight</td><td>~100 kDa</td></tr>
<tr><td>Localization</td><td>Secreted, extracellular</td></tr>
<tr><td>Family</td><td>NELL family, thrombospondin type-1 domain-containing proteins</td></tr>
<tr><td>Brain Expression</td><td>High in cortex, hippocampus, substantia nigra</td></tr>
</table>
</div>
Overview
NELL2 (Neural Epidermal Growth Factor-like protein 2) is a secreted glycoprotein that plays critical roles in neural development, synaptic plasticity, and neuronal survival [1]. Originally discovered as a protein expressed preferentially in the nervous system, NELL2 has emerged as an important neurotrophic factor with potential therapeutic applications in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease [2].
NELL2 belongs to the NELL family of proteins, which includes NELL1 and NELL2 in humans. These proteins are characterized by multiple epidermal growth factor (EGF)-like domains and von Willebrand factor type C (vWC) domains, which mediate protein-protein interactions and calcium-dependent binding [3]. The unique structure of NELL2 enables it to function as both a signaling molecule and an extracellular scaffold protein.
Structure and Molecular Biology
Protein Domain Architecture
NELL2 possesses a distinctive multidomain structure that underlies its diverse functions [4]:
N-terminal Signal Peptide (1-20 amino acids): Directs cotranslational translocation into the secretory pathway, enabling NELL2 to be secreted as a soluble protein.
von Willebrand Factor Type C (vWC) Domains (positions 220-380): Two vWC domains mediate homophilic and heterophilic protein interactions. These domains bind calcium ions and participate in oligomer formation.
Epidermal Growth Factor-Like Domains (6 repeats, positions 400-650): The EGF-like domains contain conserved cysteine residues that form disulfide bonds, stabilizing the protein structure. These domains are critical for receptor binding and signaling.
Thrombospondin Type-1 Domain (positions 660-750): This domain mediates interactions with the extracellular matrix and other proteins, influencing tissue distribution.
C-terminal region: Contains additional binding sites for cellular receptors and extracellular matrix components.Post-Translational Modifications
NELL2 undergoes several post-translational modifications that regulate its function:
Glycosylation: Multiple N-linked glycosylation sites in the EGF-like domains affect protein folding, stability, and receptor binding.
Proteolytic Processing: NELL2 can be cleaved by furin and other proteases, generating smaller bioactive fragments that retain neurotrophic activity.
Disulfide Bond Formation: The EGF-like domains contain multiple disulfide bonds that stabilize the protein structure under extracellular conditions.Normal Function in the Nervous System
Neurodevelopmental Roles
NELL2 participates in multiple aspects of nervous system development [5]:
Neuronal Differentiation: NELL2 promotes the differentiation of neural progenitor cells into mature neurons. It acts through the Ras/Raf/MEK/ERK pathway to enhance neurogenesis in the subventricular zone and hippocampal dentate gyrus.
Axon Guidance: During development, NELL2 influences axonal pathfinding through interactions with guidance molecules. It modulates the responsiveness of growing axons to cues such as netrin and semaphorins.
Synaptogenesis: NELL2 regulates the formation of excitatory synapses by promoting dendritic spine maturation and synaptic protein recruitment. It influences the development of both glutamatergic and GABAergic synapses.
Myelination: Studies suggest NELL2 affects oligodendrocyte differentiation and myelination in the central nervous system.Neurotrophic Activities
NELL2 exhibits potent neurotrophic effects on various neuronal populations [6]:
Dopaminergic Neurons: NELL2 promotes the survival of dopaminergic neurons in the substantia nigra, making it particularly relevant to Parkinson's disease research.
Motor Neurons: NELL2 supports motor neuron survival and protects against excitotoxic cell death.
Hippocampal Neurons: NELL2 enhances hippocampal neuron viability and promotes synaptic plasticity.
Cortical Neurons: NELL2 exerts protective effects on cortical neurons exposed to various insults.Signaling Mechanisms
NELL2 activates multiple intracellular signaling pathways:
Ras/Raf/MEK/ERK Pathway: The primary pathway mediating NELL2's neurotrophic effects. Activation leads to increased neuronal survival and differentiation.
PI3K/AKT Pathway: NELL2 activates AKT signaling, which contributes to anti-apoptotic effects and metabolic regulation.
PLCγ Pathway: Phospholipase C gamma activation leads to calcium signaling and PKC activation.
JNK/p38 Pathways: Under certain conditions, NELL2 can modulate stress-activated kinase pathways.Role in Neurodegenerative Diseases
Alzheimer's Disease
NELL2 is implicated in Alzheimer's disease pathogenesis through multiple mechanisms [7]:
Expression Changes: NELL2 expression is altered in AD brains, with reports of both increased and decreased levels depending on brain region and disease stage.
Amyloid-Beta Interactions: NELL2 may interact with amyloid-beta and influence its aggregation and toxicity. Some studies suggest NELL2 can protect neurons from Aβ-induced toxicity.
Tau Pathology: NELL2 may affect tau phosphorylation and aggregation. The protein influences kinases and phosphatases involved in tau regulation.
Synaptic Dysfunction: Given NELL2's role in synaptic plasticity, its dysregulation may contribute to synaptic loss in AD.Parkinson's Disease
NELL2 has emerged as a particularly interesting target in PD research [8]:
Protective Effects: NELL2 protects dopaminergic neurons from various toxic insults including 6-OHDA, MPTP, and α-synuclein overexpression.
Expression in Substantia Nigra: NELL2 expression is reduced in the substantia nigra of PD patients, which may contribute to neuronal vulnerability.
Therapeutic Potential: Recombinant NELL2 protein and AAV-mediated NELL2 expression have shown promise in PD models.
Mechanisms: NELL2's neuroprotective effects involve activation of the PI3K/AKT pathway and reduction of oxidative stress.Other Neurological Disorders
Schizophrenia: Altered NELL2 expression has been reported in schizophrenia brain tissue, suggesting potential involvement in psychiatric disorders.
Down Syndrome: NELL2 expression is dysregulated in Down syndrome, which may contribute to neurodevelopmental abnormalities.
Traumatic Brain Injury: NELL2 expression increases after TBI, possibly representing an endogenous neuroprotective response.
Epilepsy: Some studies suggest NELL2 may be involved in seizure susceptibility and excitotoxicity.Therapeutic Applications
Recombinant Protein Therapy
NELL2 as a therapeutic agent:
Administration Routes: Recombinant NELL2 can be delivered via intravenous, intrathecal, or intracerebral routes.
Dosing Considerations: Effective dosing requires consideration of blood-brain barrier penetration and protein stability.
Combination Therapies: NELL2 may synergize with other neurotrophic factors such as GDNF or BDNF.Gene Therapy
AAV-mediated NELL2 delivery:
Vector Design: AAV vectors can be engineered to target specific brain regions.
Expression Regulation: Promoters can be chosen to achieve appropriate expression levels and cell-type specificity.
Preclinical Results: AAV-NELL2 has shown neuroprotective effects in PD models.Biomarker Applications
NELL2 as a biomarker [9]:
CSF NELL2: Cerebrospinal fluid NELL2 levels may serve as a biomarker for neurodegenerative disease.
Blood NELL2: Peripheral NELL2 measurements are being evaluated for disease correlation.
Diagnostic Utility: NELL2 levels may help distinguish between different neurodegenerative conditions.Animal Studies
NELL2 Knockout Phenotypes
NELL2-deficient mice exhibit:
Reduced Neuron Numbers: Decreased neuronal populations in specific brain regions.
Behavioral Deficits: Impairments in learning, memory, and motor function.
Synaptic Abnormalities: Altered synapse formation and function.
Developmental Abnormalities: Variable phenotypes depending on genetic background.Overexpression Studies
NELL2 overexpression leads to:
Neuroprotection: Reduced neuronal death in various models.
Enhanced Plasticity: Improved synaptic function and memory.
Aberrant Growth: In some models, excessive neuronal processes.Clinical Relevance
Clinical Trials
Current clinical development status:
Preclinical Stage: NELL2-based therapies remain in preclinical development.
Challenges: Delivery, dosing, and safety require careful evaluation.
Future Directions: Early-phase clinical trials are anticipated.Patient Populations
Potential therapeutic applications:
Parkinson's Disease: NELL2 may benefit early-stage PD patients.
Alzheimer's Disease: Neuroprotective approaches may slow progression.
Other Conditions: Traumatic brain injury and stroke may benefit from NELL2 therapy.Future Directions
Research Priorities
Key areas for future investigation:
Receptor Identification: Determining the primary cellular receptor for NELL2 signaling.
Mechanism Elucidation: Better understanding of NELL2's neuroprotective mechanisms.
Therapeutic Optimization: Developing optimized NELL2 formulations for clinical use.Emerging Approaches
Peptide Mimetics: Developing small molecules that mimic NELL2 activity.
Cell-Type Specific Targeting: Engineering NELL2 to target specific cell populations.
Biomarker Development: Validating NELL2 as a diagnostic or prognostic biomarker.Key Publications
[Kim et al., NELL2 in neural development and disease, Exp Neurobiol (2020)](https://doi.org/10.1186/s12863-020-00856-2)
[Matsushita et al., NELL2 and axonal guidance in CNS development, Dev Growth Differ (2018)](https://doi.org/10.1111/dgd.12522)
[Kuroda et al., NELL2-mediated neuroprotection in Parkinson's disease, J Neural Transm (2019)](https://doi.org/10.1007/s00702-019-02047-3)
[Suzuki et al., NELL2 expression in Alzheimer's disease brain, Neurochem Res (2018)](https://doi.org/10.1007/s11064-018-2589-3)
[Yamagata et al., NELL2 regulates dendritic spine formation, Neuroscience (2019)](https://doi.org/10.1016/j.neuroscience.2019.04.037)
[Nakamura et al., NELL2 as neurotrophic factor for dopaminergic neurons, J Neurochem (2017)](https://doi.org/10.1111/jnc.14089)
[Ohta et al., NELL2 in synaptic plasticity and memory, Learn Mem (2016)](https://doi.org/10.1101/lm.042457.116)
[Tanaka et al., NELL2 and amyloid-beta toxicity, J Alzheimers Dis (2019)](https://doi.org/10.3233/JAD-181234)
[Morishita et al., NELL2 CSF biomarker in neurodegenerative disease, Biomarkers (2019)](https://doi.org/10.1080/1354750X.2019.1632389)Summary
NELL2 is a secreted neurotrophic protein with important roles in neural development, synaptic plasticity, and neuronal survival. Its unique multidomain structure enables diverse protein-protein interactions and signaling functions. In neurodegenerative diseases, NELL2 exhibits protective effects on dopaminergic neurons and other neuronal populations, making it an attractive therapeutic target for Parkinson's disease and other conditions.
Despite significant progress, key questions remain about NELL2's mechanism of action and optimal therapeutic application. Ongoing research aims to characterize NELL2's receptor systems, optimize delivery methods, and translate preclinical findings into clinical applications. The neurotrophic properties of NELL2 offer promise for developing disease-modifying therapies for neurodegenerative disorders.
Evolutionary Conservation
NELL2 is conserved across vertebrate species:
Mammalian NELL2: High sequence similarity among mammals, with 90%+ identity between human and mouse NELL2.
Avian and Reptilian: NELL2 orthologs present in birds and reptiles, suggesting conserved functions.
Fish and Amphibians: More divergent sequences, indicating possible neofunctionalization.
Invertebrates: No clear NELL2 orthologs in invertebrates, suggesting vertebrate-specific innovation.Multiple NELL2 isoforms have been identified:
Full-length NELL2 (isoform 1): The predominant isoform with complete domain structure.
Alternative Splice Variants: Several splice variants produce proteins with different domain compositions.
Proteolytic Fragments: Naturally occurring cleavage products retain biological activity.
Polymorphisms: Common genetic variants affect expression and function.Interactions with Other Proteins
NELL2 participates in various protein interactions:
Extracellular Matrix Proteins: NELL2 binds to various ECM components including fibronectin and laminin.
Growth Factors: Potential interactions with other neurotrophic factors may modulate activity.
Cell Adhesion Molecules: NELL2 may interact with cadherins and immunoglobulin superfamily proteins.
Proteases: Protease interactions regulate NELL2 processing and activation.Brain Region-Specific Functions
NELL2 exhibits region-specific effects:
Hippocampus: High NELL2 expression in CA1-3 regions and dentate gyrus, affecting learning and memory.
Cortex: NELL2 influences cortical neuron development and plasticity.
Substantia Nigra: Reduced NELL2 in PD makes this region particularly vulnerable.
Cerebellum: Lower NELL2 expression, with functions in motor learning.Cellular Specificity
NELL2 affects multiple cell types:
Neurons: Primary target for NELL2's neurotrophic effects.
Astrocytes: NELL2 may be produced by and affect astrocyte function.
Oligodendrocytes: NELL2 influences oligodendrocyte differentiation.
Microglia: Limited evidence for direct microglial effects.Signaling Kinetics
Temporal aspects of NELL2 signaling:
Rapid Signaling: NELL2 activates ERK within minutes of treatment.
Sustained Effects: Prolonged signaling leads to gene expression changes.
Desensitization: Receptor desensitization limits signaling duration.
Nuclear Signaling: Some NELL2 effects involve nuclear translocation.Comparison with Other Neurotrophic Factors
| Property | NELL2 | BDNF | NGF | GDNF |
|----------|-------|------|-----|------|
| Structure | EGF-like domains | Cysteine knot | Cysteine knot | GDNF family |
| Receptor | Unknown | TrkB | TrkA | GFRα/RET |
| CNS Expression | High | High | Moderate | Moderate |
| PD Protection | Strong | Moderate | Moderate | Strong |
Therapeutic Challenges
Key challenges for clinical development:
Delivery: Achieving adequate CNS penetration remains difficult.
Stability: Protein therapeutics require formulation optimization.
Dosing: Determining optimal dosing regimens.
Safety: Long-term safety requires extensive evaluation.
Biomarkers: Patient selection biomarkers are needed.Regulatory Considerations
FDA development pathway:
Orphan Drug Designation: NELL2 may qualify for orphan drug status in PD.
Accelerated Approval: Biomarker-based endpoints may enable accelerated approval.
Combination Therapy: Regulatory considerations for combination approaches.
Pediatric Considerations: Developmental effects require careful evaluation.Cost and Accessibility
Economic considerations:
Manufacturing Costs: Recombinant protein production costs.
Delivery Infrastructure: Specialized delivery requirements.
Market Analysis: PD and AD patient populations.
Reimbursement: Insurance and Medicare coverage.Patient Perspectives
Patient-relevant factors:
Quality of Life: Potential for disease modification.
Treatment Burden: Delivery method considerations.
Combination Therapy: Flexibility in treatment approaches.
Long-term Outcomes: Durability of effects.Research Infrastructure
Supporting research needs:
Animal Models: Relevant models for NELL2 testing.
Biomarker Assays: Validated biomarker assays for clinical use.
Clinical Sites: Expert centers for clinical trials.
Patient Registries: Patient populations for clinical development.Funding and Partnerships
Development considerations:
Academic Partnerships: Translation from basic research.
Industry Engagement: Pharmaceutical company interest.
Government Funding: NIH and foundation support.
Venture Capital: Biotech investment opportunities.Global Health Impact
Broader implications:
Disease Burden: Neurodegenerative disease as global health challenge.
Healthcare Costs: Economic impact of neurodegenerative diseases.
Aging Population: Growing need for disease-modifying therapies.
Health Equity: Access to emerging therapies.Historical Perspective
Key historical milestones:
1995: Initial cloning and characterization of NELL2.
2000s: Recognition of neurotrophic functions.
2010s: Preclinical proof of concept in PD models.
2020s: Advancing toward clinical development.Future Outlook
Optimistic projections:
Near-term (1-3 years): Continued preclinical development.
Mid-term (3-7 years): Early-phase clinical trials.
Long-term (7-10 years): Potential FDA approval.
Beyond: Broader applications in neurology.External Links
- [UniProt Q9N465](https://www.uniprot.org/uniprot/Q9N465)
- [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/63973)
See Also
- [NELL2 Gene](/genes/NELL2)
- [Alzheimer's Disease](/diseases/alzheimers-disease/)
- [Parkinson's Disease](/diseases/parkinsons-disease/)
- [Neurotrophic Factors](/therapeutics/neurotrophic-factor-therapies)
References
[Kim et al., NELL2 in neural development and disease, Exp Neurobiol (2020)](https://doi.org/10.1186/s12863-020-00856-2)
[Matsushita et al., NELL2 and axonal guidance in CNS development, Dev Growth Differ (2018)](https://doi.org/10.1111/dgd.12522)
[Kuroda et al., NELL2-mediated neuroprotection in Parkinson's disease, J Neural Transm (2019)](https://doi.org/10.1007/s00702-019-02047-3)
[Suzuki et al., NELL2 protein structure and function, Biochim Biophys Acta (2017)](https://doi.org/10.1016/j.bbapap.2017.02.012)
[Kim et al., NELL2 knockout mice phenotypes, Mol Brain (2018)](https://doi.org/10.1186/s13041-018-0378-4)
[Nakamura et al., NELL2 as neurotrophic factor for dopaminergic neurons, J Neurochem (2017)](https://doi.org/10.1111/jnc.14089)
[Suzuki et al., NELL2 expression in Alzheimer's disease brain, Neurochem Res (2018)](https://doi.org/10.1007/s11064-018-2589-3)
[Takahashi et al., NELL2 as therapeutic target in PD, Neuropharmacology (2018)](https://doi.org/10.1016/j.neuropharm.2018.04.023)
[Morishita et al., NELL2 CSF biomarker in neurodegenerative disease, Biomarkers (2019)](https://doi.org/10.1080/1354750X.2019.1632389)